15:11 | 21/02/2017 Science - Technology
(VEN) - Abbott, global healthcare company, has recently been honored among most of innovative companies 2017 by Fast Company, a credential American business magazine.
According to that, Abbott has been placed among Top 10 business in Biotech. To produce the 2017 list, Fast Company reporters surveyed thousands of enterprises across the globe to identify the most notable innovations of the year and trace the impact of those initiatives on business, industry, and the larger culture.
Previously, Abbott has been named in Top 100 Global Innovators for four consecutive years. Two out of its breakthrough innovations were also recognized on Best of What’s News list published by Popular Science Magazine.
|AbsorbTM stent - the world's first fully dissolving heart stent|
An innovative device which received many innovation awards is AbsorbTM stent - the world's first fully dissolving heart stent, researched and developed by Abbott to treat coronary artery disease (CAD). Approved by the Food and Drug Administration in the U.S., Absorb is implanted in patients around the globe and available in more than 100 countries. Absorb is a first-of-its-kind device that functions like a permanent, metallic stent by opening a blocked artery in the heart, restoring blood flow and providing relief from symptoms of coronary artery disease (CAD). An unrestricted vessel with restored vessel function has the potential to flex, pulse and dilate in response to various demands on the heart, based on people's lifestyle and activities, and allows for potential future treatment options.
In Vietnam, Absorb was introduced in December 2012 and since then, has seen an upward adoption curve with more than 400 implantations on patients. The device has fully dissolved after 3 years of implantation to patients, leaving nothing behind but a restored vessel.
Prof. Krishna Sudhir, Vice President of Medical Affairs at Abbott Vascular shared: “We will continue to invest in innovating new, more high-quality solutions that are more accessible to Vietnamese people – across the spectrum of health - for all stages of life, bringing them a better and full life.”
As a global healthcare company, innovation has been the engine in every company’s activities. Learning more about Abbott’s latest breakthroughs:
- Realtime Zika Test: Authorized by the FDA, the test is to identify Zika virus ribonucleic acid (RNA) in plasma, serum and urine to detect the virus in whole blood.
- MitraClip: Clinical data from MitraClip patients show an immediate reduction of mitral regurgitation and a low average hospital length of stay of 2.9 days. Many patients report they experience significant improvement in symptoms and quality of life soon after the procedure.